Therefore, the objective of the present study was to evaluate the risk of new-onset stroke (NOS) associated with the prescription of SGLT2 inhibitors in a nationwide cohort study of patients with type 2 DM in Taiwan. Here, SLC5A2 is linked to Stroke.